An Overview of Naloxone and FDA's Efforts to Expand Access
April 6, 2022 - December 31, 2023
This webinar was designed to aid healthcare professionals in understanding the forms of naloxone that are available for the emergency treatment of acute opioid overdose and also increased knowledge of steps that FDA has taken to expand community access to naloxone.
- Naloxone hydrochloride nasal spray (Narcan Nasal Spray) labeling: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208411Orig1s002lbl.pdf
- Naloxone hydrochloride injection sol. (Evzio) labeling: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209862lbl.pdf
- New Recommendations for Naloxone https://www.fda.gov/drugs/drug-safety-and-availability/new-recommendations-naloxone
- Cohen BR, Mahoney KM, Baro E, Squire C, Beck M, Travis S, Pike-McCrudden A, Izem R, Woodcock J. FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone. N Engl J Med. 2020 May 28;382(22):2129-2136. doi: 10.1056/NEJMsa1912403 https://www.nejm.org/doi/full/10.1056/NEJMsa1912403
- Guidance for Industry Label Comprehension Studies for Nonprescription Drug Products https://www.fda.gov/media/75626/download
- Describe what naloxone is, how it works, and the availability of products for treatment of acute opioid
overdose - Identify the steps FDA has taken to encourage prescribers to discuss naloxone with patients
- Explain FDA’s work to support the development of an over-the-counter (OTC) naloxone product
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, Certified Public Health (CPH) Professionals, and physician assistants.
Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Faculty
- Cohen, Barbara, MPA, Social science analyst, FDA - nothing to disclose
- Liberatore, Mark, PharmD, RAC, Deputy Director for Safety, HHS/FDA/CDER/OND/ON/DAAP - nothing to disclose
- Moncur, Megan, MS, Associate Director for Opioid Policy, FDA - nothing to disclose
Planning Committee
- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Cao, Christian, MPAS, PA-C, Cross-Discipline Safety Advisor, FDA/CDER/OSE/OPE - nothing to disclose
- De Fronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- Kapoor, Rama, MD, Senior Physician, FDA - nothing to disclose
- Nguyen-Chu, Thanh, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Paraoan, Dianne, MPH, BSN, RN, Associate Director for Regulatory Affairs, FDA/ CDER/ OMP - nothing to disclose
CE Consultation and Accreditation Team
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
All relevant financial relationships have been mitigated.
Registration is complimentary; therefore refunds are not applicable.
Must attend 100% of the activity.
Initial Release Date
January 14, 2021
Revised Date
April 6, 2022
Expiration Date
December 31, 2023